Steglatro

Active Ingredient(s): Ertugliflozin
FDA Approved: * December 19, 2017
Pharm Company: * MERCK SHARP DOHME
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Steglatro Overview

Ertugliflozin (INN; trade name Steglatro) is a drug for the treatment of Type 2 diabetes. In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin.[1] Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins. References ^ "FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes". MedScape. This drug a...

Read more Steglatro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ertugliflozin

Recent Steglatro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ertugliflozin
  • Tablet: 15mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Steglatro: (2 results)

Sorted by National Drug Code
  • 0006-5363 Steglatro 5 mg Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.
  • 0006-5364 Steglatro 15 mg Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.

Other drugs which contain Ertugliflozin or a similar ingredient: (5 results)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 22 February 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.